Loading
In a United States cohort covering 231,596 people diagnosed between 1995 and 2009, those who filed for bankruptcy after a cancer diagnosis had a mortality hazard ratio of 1.79 against propensity-matched people who did not. In a national survey of people over 50, 42.4 per cent had depleted their entire assets two years after diagnosis, losing an average of 92,098 dollars.
The corpus already carries financial toxicity as a term and financial navigation as a technology, and this record is the part they do not cover: what happens to money after active treatment ends, when the income has gone and the costs have not.
The American evidence is the strongest because the data linkage exists there. A retrospective cohort linked medical, personal, legal and bankruptcy records in the Western District of Washington for 1995 to 2009 and found that people with cancer were 2.65 times more likely to file for bankruptcy than people without. Younger patients had rates two to five times higher than patients aged 65 or over, which the authors read as Medicare and Social Security cushioning the older group.
The follow-up asked whether that mattered to survival. Western Washington registry records for 231,596 people diagnosed between 1995 and 2009 were linked to federal bankruptcy records; 4,728 filed. After propensity matching on demographics and clinical factors, 3,841 remained in each group, with a mean age of 53, mean income of 49,000 dollars, 84 per cent with local or regional stage disease and similar initial treatment in both groups. The adjusted hazard ratio for mortality in those who filed was 1.79 (95 per cent confidence interval 1.64 to 1.96), with the highest ratios in colorectal, prostate and thyroid cancers, and excluding distant-stage disease did not change the result. The authors are careful about what that means: severe financial distress "appears to be a risk factor for mortality", and "Further research is needed to understand the process by which extreme financial distress influences survival". An association in matched observational data is not a demonstration that bankruptcy kills people; it is a strong signal that the two travel together and a reason to treat money trouble as a clinical finding.
The third dataset covers assets rather than bankruptcy. A longitudinal analysis of a national survey of Americans over 50 covered an estimated 9.5 million new cancer diagnoses between 2000 and 2012, using the two years before diagnosis as a historical control. Two years after diagnosis, 42.4 per cent had depleted their entire life's assets, with average losses of 92,098 dollars; at four years, 38.2 per cent remained in that position. Higher odds went with worsening cancer, a requirement for continuing treatment, being female, Medicaid or no insurance, being retired, increasing age, income and household size, and several clinical characteristics.
Why the mechanism differs by country, and why the numbers do not transfer. In a system where treatment is billed, the damage is done by bills, co-payments, insurance design and the loss of employer-provided cover when a job ends. In a tax-funded system the treatment is free at the point of use and the damage is done by the same loss of income, plus travel to appointments, hospital parking, heating a house that is now occupied all day, childcare, new clothes for a changed body, and prescription and dental charges where they apply. The European review cited on the right-to-be-forgotten record found objective financial burden in 41 to 48 per cent and subjective strain in 7 to 39 per cent of people with cancer "even in public health care systems", which is the best available indication that the problem is not confined to one financing model. OnCo did not verify a United Kingdom figure from a primary source in this round and therefore prints none; the charity helplines that produce those estimates are also the route to a free benefits check, which is the useful action rather than the number.
What can be done, graded honestly. Financial navigation, meaning a trained person who screens for money problems and connects patients to assistance, insurance review and legal help, has its own record in the corpus. The European review's assessment of its evidence is the one to hold: "Eleven trials of early financial navigation produced only modest, short-term improvements." That is a real effect and a small one, and it is still better than the alternative of nobody asking. Screening for financial hardship at diagnosis, treating it as a measured side effect rather than a private misfortune, is the subject of several proposals already in this corpus.
The practical sequence for a reader, which is the same in both systems and is almost never given at the right time: have the benefits conversation in the first month rather than the third, because entitlements are not backdated far and because the paperwork takes weeks; ask about travel costs, which are reimbursable in several systems and almost never claimed; and tell the team, because a treatment plan that a person cannot afford to attend is not a treatment plan.
Financial harm from cancer compounds. Lost income reduces the capacity to absorb a shock at the moment the shock arrives, and the responses available to a household under pressure, drawing down savings, missing payments, skipping medication and delaying follow-up, each raise the probability of the next problem. That is the proposed mechanism linking severe financial distress to worse survival, and it is why the intervention point is early rather than at the point of insolvency.
Query for this technology: (TITLE:"Money after treatment: what the cost of cancer does once the treatment has finished" OR ABSTRACT:"Money after treatment: what the cost of cancer does once the treatment has finished") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Money after treatment: what the cost of cancer does once the treatment has finished, not a curated reading list.
Shares Screening for distress: what the thermometer can and cannot do, Quality of life, Survivorship care and late-effects surveillance, Survivorship and late effects are neglected and the tags rejuvenation, survivorship, psychosocial.
Shares Screening for distress: what the thermometer can and cannot do, Quality of life, Survivorship care and late-effects surveillance, Survivorship and late effects are neglected and the tags rejuvenation, survivorship, psychosocial.
Shares Screening for distress: what the thermometer can and cannot do, Quality of life, Survivorship and late effects are neglected, HR-positive / HER2-negative breast cancer and the tags rejuvenation, survivorship, psychosocial.
Shares Quality of life, Survivorship care and late-effects surveillance, Survivorship and late effects are neglected, HR-positive / HER2-negative breast cancer and the tags rejuvenation, survivorship, psychosocial.
Shares Quality of life, Survivorship and late effects are neglected, Multiple myeloma, HR-positive / HER2-negative breast cancer and the tags rejuvenation, survivorship, psychosocial.
Shares Screening for distress: what the thermometer can and cannot do, Quality of life, Survivorship and late effects are neglected, HR-positive / HER2-negative breast cancer and the tags rejuvenation, survivorship, psychosocial.
Shares Quality of life, Survivorship care and late-effects surveillance, Survivorship and late effects are neglected, HR-positive / HER2-negative breast cancer and the tags rejuvenation, survivorship, psychosocial.
Shares Quality of life, Survivorship care and late-effects surveillance, Survivorship and late effects are neglected, HR-positive / HER2-negative breast cancer and the tags rejuvenation, survivorship, psychosocial.